Clinical Trials: Breast Center
For more information about breast cancer clinical trials at UNC, call 919-966-4432 or (toll free) 1-877-668-0683 to speak with Nancy Pope, Donna Rowe, or Maureen Beeler.
UNC researchers Lisa Carey, MD, Claire Dees, MD, Jim Evans, MD, PhD, David Flockhart, MD, PhD, William Irvin Jr., MD, Howard McLeod, PharmD, and Karen Weck, MD, are conducting a pilot trial that uses genetics to determine tamoxifen dosing for breast cancer. Watch WRAL's video.
Hear from Dr. Karin True, a participant in the tamoxifen trial.
Photo courtesy of www.ipit.unc.edu/.
A partial list of priority breast cancer trials at UNC follows below.
Early Breast Cancer
LCCC0801: Evaluating the Role of Genotype in Tamoxifen Therapy for Breast Cancer (highlighted above)
PI: Lisa Carey, MD, 919-966-8218
Study Coordinator: Donna Rowe, RN, 919-966-4432, (toll free) 1-877-668-0683
DFCI-07-199: Adjuvant paclitaxel and trastuzumab for node-negative HER2- positive breast cancer
PI: Lisa Carey, MD, MS, 919-966-8218
Study Coordinator: Maureen Beeler, RN, 919-966-4432, (toll free) 1-877-668-0683
LCCC0804 (PROACT - Preserving Reproductive Opportunity After Cancer Treatment): Emergency In Vitro Fertilization with Embryo Cryopreservation
PI: Jennifer Mersereau, MD, 919-966-5283
LCCC0402: A Couples Approach to Enhance Breast Cancer Survivorship
PI: Don Baucom, PhD, 919-962-5035
Recurrent Breast Cancer
All Types
A6181068: A Phase II Study of Sunitinib Malate Single Agent for the Treatment of Women with Advanced Breast Cancer
PI: Claire Dees, MD, 919-843-7714
Study Coordinator: Nancy Pope, RN, 919-966-4432, (toll free) 1-877-668-0683
Locoregionally Recurrent
LCCC0411: Phase I Radiosensitization Study of GW572016 with Biologic Correlates in Locoregionally Recurrent Breast Cancer
PI: Claire Dees, MD, 919-843-7714
Study Coordinator: Maureen Beeler, RN, 919-966-4432, (toll free) 1-877-668-0683
HER2+
LCCC0418: Phase II Trial Evaluating the Toxicity and Efficacy of a Multiepitope Dendritic Cell Vaccine Given with Trastuzumab and Vinorelbine for the Treatment of Women with Metastatic Breast Cancer that Express HLA-A0201 and Whose Tumors Overexpress Her-2/NEU
PI: Jonathan Serody, MD, 919-966-8644
Study Coordinator: Kim Keller, RN, 919-966-4432, (toll free) 1-877-668-0683
TBCRC003-06-213: A Phase 2 Study of Lapatinib in Combination with Trastuzumab in Patients with HER2-Positive, Metastatic Breast Cancer
PI: Claire Dees, MD, 919-843-7714
Study Coordinator: Maureen Beeler, RN, 919-966-4432, (toll free) 1-877-668-0683
1200-11: Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast cancer after failure of trastuzumab therapy
PI: Lisa Carey, MD,919-966-8218
Study Coordinator: Nancy Pope, RN, 919-966-4432, (toll free) 1-877-668-0683
